skip to main content

Rogel members will present at upcoming ASCO Annual Meeting

Date Visible: 
05/26/2022 - 11:30am

Media contact: Anna Megdell734-764-2220

ASCO Conference Logo - conference is in Chicago, June 3 - 7

More than 30 Rogel Cancer Center-led research efforts will be presented during the 2022 ASCO Annual Meeting, running June 3-7 at McCormick Place in Chicago, Illinois, and online.

Tag @UMRogelCancer and use #ASCO22 to maximize the reach and impact of your colleagues’ work.

Presenter information is sometimes incomplete. If your session is missing, please email the abstract link to [email protected].

Note that some of the links below are only available to registered meeting participants.

June 4

Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
Ulka N. Vaishampayan, MBBS, FAB
2:15 PM – 2:30 PM; In-Person & Live Stream, Hall B1

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Patrick Burke, M.D.; Co-Chair
2:15 PM – 3:45 PM; In Person & On Demand, Room E450

Professional Development and Education Advances
Gregory Kalemkerian, M.D.;Co-Chair
5:30 PM – 7:00 PM; In-Person & On Demand, Room S504

Science of Oncology Award and Lecture
Lori J. Pierce, M.D.; Presenter
5:45 PM – 6:30 PM
In-Person & Live Stream, Hall B1


81 - Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
Vaibhav Sahai, M.D., M.S.; Abstract: 4094

363 - NSABP FC-10: A phase Ib study of pembrolizumab (pembro) in combination with pemetrexed (pem) and oxaliplatin (oxali) in patients with chemo-refractory metastatic colorectal cancer (mCRC).
John C. Krauss, M.D.; Abstract: 3569

269 - Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221.

Ciao-Sin Chelsea Chen; Abstract: 12023

271 - Influence of decision support persons on breast cancer treatment decisions among Latinas.

Krystal A. Morales, M.D., Ph.D.; Abstract: 12025

June 5

Less Is More: Why Saving Treatment Until Relapse Can Spare Low-Risk Patients From Toxicity
Christopher D. Lao, M.D., M.P.H.
9:15 AM – 9:30 AM; In-Person & On Demand, Room S100bc

Overview of Barriers to Ensuring Racial and Ethnic Diversity in Clinical Trials
Lori J. Pierce, M.D.; Presenter & Chair
12:30 PM – 12:45 PM; In-Person & On Demand, Room S406

Less Is More: Practical De-Implementation Science Strategies to Improve Quality
Ted A. Skolarus, M.D.
5:30 PM – 6:30 PM; In-Person & On Demand, Room E350

Contemporary Approach to the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Tycel Jovelle Phillips, M.D.
5:45 PM – 6:00 PM' In-Person & On Demand, Room E450


266- Safety of dual checkpoint-blockade with PSB205, an anti-PD-1/CTLA4 monoclonal antibody combination, manufactured and dispensed as a single product: A phase 1 study.
Rashmi Chugh, M.D.; Abstract: 2611

318 - Increased incidence of immune-mediated myocarditis in advanced skin malignancies treated with immune checkpoint inhibitors in the COVID-19 era.
Allison Gradone, M.D.; Abstract: 2664

400 - Predicting CNS penetration of precision medicine therapies in oncology: A comparison of the CNS TAP tool and the BOILED-Egg computational model.
Gianni Walker; Abstract: 2062

June 6

Symptoms and Survivorship
Michelle Mierzwa, M.D.; Co-Chair
12:30 PM – 3:30 PM; In-Person & Live Stream, Room E450

Central Nervous System Tumors
Michelle Kim, M.D.; Co-Chair
12:30 PM – 3:30 PM; In-Person & Live Stream, Room S406

Breast Cancer — Local/Regional/Adjuvant
Norah Lynn Henry, M.D., Ph.D.; Co-Chair
2:15 PM – 3:45 PM; In-Person & Live Stream, Hall B1


123b - A phase I/II multisite study of rucaparib and pembrolizumab maintenance therapy in stage IV non-squamous non–small cell lung cancer after initial therapy with carboplatin, pemetrexed, and pembrolizumab.
Angel Qin, M.D.; Abstract: TPS9138

241 - Transcriptional profiling of matched biopsies reveals molecular determinants of enzalutamide resistance.
Thomas Westbrook, M.D.; Abstract: 5058

273 - Recurrence, metastasis, and survival after radical prostatectomy in the era of advanced treatments.
Kristian D. Stensland, M.D.; Abstract: 5090

286a - Focal radiation with pulsed systemic therapy of abiraterone, androgen deprivation therapy (ADT), olaparib towards castration-sensitive oligometastatic prostate cancer (FAALCON Trial).
Zachery R Reichert, M.D., Ph.D.; Abstract: TPS5113

271 - The impact of clinical trial enrollment on specialty palliative care utilization in pediatric patients with high-grade gliomas.
Holly Roberts; Abstract: 10057

200 - A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Ulka N. Vaishampayan, MBBS, FAB; Abstract: 5016

351 - Polypharmacy and premature aromatase inhibitor (AI) discontinuation in older women with breast cancer.
Elizabeth Joyce; Abstract: 6568

406 - Comparison of simulated outcomes between stool- and blood-based colorectal cancer screening tests.
A. Mark Fendrick, M.D.; Abstract: 10529

46 - Oncologist knowledge of cost of genetic testing.
Shayna Weiner; Abstract: 10591

476 - Effects of healthcare provider recommendation for genetic testing.
Emerson Delacroix; Abstract: 10601

477 - A pilot study to increase cascade genetic testing in families with hereditary cancer syndromes.
Steven J. Katz, M.D., M.P.H.; Abstract: 10602

480 - Genetic risk assessment in primary care settings: An evaluation of NCCN guidelines.
Kara J. Milliron, M.S., C.G.C.; Abstract: 10605

June 7